Showing 2391-2400 of 3039 results for "".
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Formosa and AimMax Submit NDA to the FDA for APP13007 for Postoperative Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/formosa-and-aimmax-announce-the-nda-submission-to-the-fda-for-app13007-for-postoperative-inflammation-and-pain-following-ocular-surgery/2481602/Formosa Pharmaceuticals and AimMax Therapeutics announced the submission of a new drug application to the FDA for APP13007, a novel aqueous nanosuspension formulation of the corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surger
- Glaukos Announces FDA Acceptance of NDA Submission for iDose TRhttps://modernod.com/news/glaukos-announces-fda-acceptance-of-nda-submission-for-idose-tr/2481599/Glaukos announced it has received the “Day 74” notification from the FDA acknowledging the previously submitted new drug application (NDA) for iDose TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review. The Prescription Drug U
- Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-completes-enrollment-ahead-of-schedule-in-its-phase-12a-trial-of-ea-2353-for-retinitis-pigmentosa/2481594/Endogena Therapeutics has announce that it has completed patient enrollment ahead of schedule in its phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is now in the expansion cohort stag
- Johnson & Johnson Vision to Present and Support 43 Company-Sponsored and Investigator-Led Studies at ASCRShttps://modernod.com/news/johnson-johnson-vision-to-present-and-support-43-company-sponsored-and-investigator-led-studies-at-ascrs/2481593/Johnson & Johnson Vision will present and support 43 company-sponsored and investigator-led studies evaluating innovation, outcomes and satisfaction rates across its surgical portfolio at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, May 5-8
- Julie Schornack, OD, Named First Female President of Marshall B. Ketchum Universityhttps://modernod.com/news/julie-schornack-od-named-first-female-president-of-marshall-b-ketchum-university/2481585/Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution in Fullerton, California has introduced Julie A. Schornack, OD, MEd, as its next president to lead the university. Dr. Schornack is the first female p
- VMG Health Acquires Healthcare Consulting Firm BSM Consultinghttps://modernod.com/news/vmg-health-acquires-healthcare-consulting-firm-bsm-consulting/2481579/VMG Health announced it has acquired BSM Consulting, a health care consulting firm with offices in Reno, Nevada and Phoenix. Financial terms of the acquisition were not disclosed. VMG Health is owned by VMG employees and Northlane Capital Partners (NCP). NCP inv
- New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023https://modernod.com/news/new-data-on-two-nicoxs-assets-ncx-470-and-ncx-1728-presented-at-arvo-2023/2481567/Nicox announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans. Poster title: NCX 470, a nitric oxide (NO)-donating&
- GenSight Biologics Withdraws its EMA Application for Lumevoqhttps://modernod.com/news/gensight-biologics-withdraws-its-ema-application-for-lumevoq/2481559/GenSight Biologics announced that it has decided to withdraw an application with the European Medicines Agency (EMA) seeking approval of Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The moves comes after the Committee for Advanced Therapies (CAT
- CooperVision: Study Links Individual OSDI Responses to Clinical Measures, Spotlighting Possible Treatmenthttps://modernod.com/news/coopervision-study-links-individual-osdi-responses-to-clinical-measures-spotlighting-possible-treatment/2481551/Preliminary results from a new study indicate that individual question responses within the widely-used Ocular Surface Disease Index (OSDI) symptom questionnaire can be correlated to specific clinical measures, providing eye care professionals better insight on treatment pathways. The Cooper